Skip to content
Head to head

Palvella Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: PVLA · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

PVLA +75.0%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
PVLAVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price142.85515.02
Change today-2.00%-1.08%
1-year return+56.1%+22.0%
Market cap$2.09B$130.58B
52-week range72.23 – 179.95412.27 – 568.67
Valuation
P/E (TTM)-25.8333.14
P/E percentile, own 5-yr range27th99th
P/B10.556.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.7115.32
Net profit (TTM)$-54.23M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-43.06M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership108.9%96.8%
Insider activity (12mo)29 buy / 20 sell28 buy / 22 sell
Short interest (% of float)18.1%1.9%
Analyst consensus100% buy (12)95% buy / 5% hold (21)
Analyst price target$228 (+59%)$624 (+21%)
StockVane view
StockVane Quant RatingC (86)C (68)
Company
Employees296,400
Founded20151989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.